Table 1.
Cohorts.
| Sample size | Age range | ||||||
|---|---|---|---|---|---|---|---|
| Cohort | Name | Type | Data | Control | Case | 5% | 95% |
| Pitt (cross-validated) | Pitt-aging | Postmortem | Transcriptomics + Genetics | 204 | 0 | 22.0 | 72.9 |
| Pitt-MDD MD2_ACC_F | Pitt-MDD1 | Postmortem | Transcriptomics | 13 | 13 | 26.5 | 64.8 |
| Pitt-MDD MD2_DLPFC_F | Pitt-MDD2 | Postmortem | Transcriptomics | 16 | 16 | 27.1 | 68.6 |
| Pitt-MDD MD2_DLPFC_M | Pitt-MDD3 | Postmortem | Transcriptomics | 14 | 14 | 28.2 | 61.7 |
| Pitt-SCZ PC L5 | Pitt-SCZ1 | Postmortem | Transcriptomics | 32 | 32 | 25.3 | 64.7 |
| Pitt-SCZ MO1 L5 | Pitt-SCZ2 | Postmortem | Transcriptomics | 16 | 16 | 37.7 | 63.4 |
| Lieber SCZ | Lieber | Postmortem + Clinical | Transcriptomics + Genetics | 99 | 88 | 17.2 | 70.3 |
| CommonMind SCZ MSSM | CMMD-SCZ1 | Postmortem + Clinical | Transcriptomics + Genetics | 115 | 85 | 42.0 | 90.0 |
| CommonMind SCZ Pitt | CMMD-SCZ2 | Postmortem + Clinical | Transcriptomics + Genetics | 73 | 36 | 24.4 | 68.6 |
| CommonMind BP MSSM | CMMD-BP1 | Postmortem + Clinical | Transcriptomics + Genetics | 115 | 11 | 41.3 | 90.0 |
| CommonMind BP Pitt | CMMD-BP2 | Postmortem + Clinical | Transcriptomics + Genetics | 73 | 31 | 24.0 | 66.9 |
| ROS-MAP AD | ROSMAP | Postmortem + Clinical | Genetics | 384 | 251 | 76.9 | 90.0 |
| Health ABC | Health ABC | Clinical | Genetics | 1794 | 0 | NA (> 65) | |
| IRL-Grey+HIP fracture studies | IRL | Clinical | Genetics | 254 | 0 | NA (> 65) | |
Sample sizes reflect sample sizes after quality control evaluation.